Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19-Reference-Cited by-同舟云学术

Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19

Published:2022-08 Issue:8 Volume:28 Page:1044-1046
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Girardin François,Manuel Oriol,Marzolini Catia,Buclin Thierry

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference11 articles.

1. Supervised Molecular Dynamics (SuMD). Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332;Pavan;J Enzym Inhib Med Chem,2021

2. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19;Hammond;N Engl J Med,2022

3. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications;Marzolini;J Antimicrob Chemother,2016

4. Physiologically-based pharmacokinetic modeling to support the clinical management of drug-drug interactions with bictegravir;Stader;Clin Pharmacol Ther,2021

5. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4;Rock;Mol Pharmacol,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nirmatrelvir (Paxlovid with Ritonavir): A 3‐Chymotrypsin‐like Protease Inhibitor for Treating SARS‐CoV‐2 Infection;Chemistry and Pharmacology of Drug Discovery;2024-08-16

2. New anti-SARS-CoV-2 aminoadamantane compounds as antiviral candidates for the treatment of COVID-19;Virus Research;2024-02

3. The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability;Pharmaceutics;2024-01-14

4. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial;eClinicalMedicine;2024-01

5. Pairwise synthetic cytotoxicity between Paxlovid and 100 frequently prescribed FDA-approved small molecule drugs on liver cells;Toxicology and Applied Pharmacology;2023-10